Pathology: mHCC - 1st line (L1); mHCC - 2nd line (L2);
mHCC - 1st line (L1) | mHCC - 2nd line (L2) | |||
LEAP 002, 0 | KEYNOTE-240, 2020 | KEYNOTE-394, 2022 | ||
pembrolizumab plus lenvatinib | 1 | T1 | ||
pembrolizumab based treatment | 1 | T1 | ||
pembrolizumab alone | 1 | T1 | ||
lenvatinib | 0 | T0 | ||
placebo | 0 | T0 | T0 |